Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8668552 | 0.86 | CYP19A1 (0.58) | CYP19A1HTR1ASIGMAR1ACHEHTR2C | |
| SCHEMBL9534253 | 0.84 | CYP19A1 (0.55) | CYP19A1HTR1ASIGMAR1ACHEHTR2C | |
| SCHEMBL7305594 | 0.81 | CYP19A1 (0.50) | CYP19A1HTR1ASIGMAR1ACHEHTR2C | |
| SCHEMBL17320387 | 0.80 | METAP1 (0.46) | CYP19A1 | |
| Hydrochloric Acid SCHEMBL9425957 | 0.80 | CYP19A1 (0.49) | CYP19A1HTR1ASIGMAR1ACHEHTR2C | |
| SCHEMBL6689014 | 0.80 | CYP19A1 (0.61) | CYP19A1HTR1ASIGMAR1ACHEHTR2C | |
| SCHEMBL6694407 | 0.80 | CYP19A1 (0.61) | CYP19A1HTR1ASIGMAR1ACHEHTR2C | |
| SCHEMBL11026228 | 0.78 | CYP19A1 (0.49) | CYP19A1HTR1ASIGMAR1ACHEALDH1A1 | |
| SCHEMBL15904627 | 0.77 | CYP24A1 (0.59) | CYP19A1SIGMAR1HTR2C | |
| SCHEMBL8668547 | 0.77 | CYP19A1 (0.58) | CYP19A1HTR1ASIGMAR1ACHEHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022026285-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | DNASE1, RNASEH1, RNASE1 | CYP19A1 2558/4885HTR1A 4375/4885SIGMAR1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.